Our survival results were comparable to the SECA II trial, with a 100% 1-year OS and an 83% 3-year OS [10]; similarly to the SECA-II trial, we refined our criteria for transplant eligibility, enrolling patients with lower liver tumour burden, better tumour response to treatment and lower serum CEA levels. This evidence concerns the gene CEACAM5 and neoplasm.